ArticleAmerican journal of preventive cardiology2026
Repeat CRP measurements and incident myocardial infarction.
Article in American journal of preventive cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The future of CV prevention science depends on how we communicate: why simultaneous publication matters.American journal of preventive cardiology · 2026Article
- Estimating residual inflammatory risk: Further insights into repeat hsCRP Testing from the UK BioBank.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation is a causal risk factor for cardiovascular disease. While individuals with elevated levels of inflammation may benefit from targeted therapy, population-level stability of inflammation over time is poorly defined, as is the relationship between repeated measures of inflammatory markers and incident myocardial infarction. C-reactive protein (CRP) is among the best-established inflammatory markers. Objectives: To examine (i) the stability of CRP over repeat measurements and (ii) the association between patterns of repeated CRP and rates of first-time myocardial infarction. Methods: The relationship between baseline and repeat assessment of CRP was analyzed in 14,960 individuals from the UK Biobank without a diagnosed underlying inflammatory condition. The association between baseline and repeat CRP and first-time myocardial infarction was estimated using a Cox proportional hazards model. Results: Among the analyzed cohort, median (IQR) age was 58 (52-63) years, 7,564 (51%) were female, and median (IQR) CRP was 1.1 (0.6-2.3) mg/L at baseline. Baseline and repeat CRP were correlated (Spearman rho 0.64) across a median (IQR) follow-up interval of 4.4 (3.7-4.9) years. Among the 10,566 (71%) individuals with non-elevated CRP (<2 mg/L) at baseline, 8,776 (83%) had non-elevated CRP at repeat, while among the 4,394 (29%) with elevated CRP at baseline, 3,127 (62%) had elevated CRP at repeat. Across median (IQR) follow-up 11.5 (11.4, 11.8) years after the repeat CRP measurement, 426 individuals (2.9%) sustained a first-time myocardial infarction. Relative to non-elevated CRP at baseline and repeat, elevated CRP at both baseline and repeat was associated with incident first-time myocardial infarction (HR = 1.66; 95% CI: 1.31-2.12; Conclusions: Persistently elevated CRP was significantly associated with incident first-time myocardial infarction. This finding highlights the importance of repeated measurement of inflammatory markers for cardiovascular risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.